PROTACs: Novel tools for improving immunotherapy in cancer.

[1]  J. Licht,et al.  Piperlongumine (PL) conjugates induce targeted protein degradation , 2023, bioRxiv.

[2]  S. Tantry,et al.  Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer , 2023, PloS one.

[3]  D. Gewirtz,et al.  The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer , 2023, Frontiers in Oncology.

[4]  Guoqiang Dong,et al.  Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer. , 2022, Journal of medicinal chemistry.

[5]  Yuzhu Hu,et al.  Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Jinfeng Hu,et al.  Regulation of programmed cell death by Brd4 , 2022, Cell death & disease.

[7]  Min Huang,et al.  Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT. , 2022, Journal of medicinal chemistry.

[8]  M. Zaki,et al.  Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities , 2022, Pharmaceuticals.

[9]  Cheng Xu,et al.  Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐Immunotherapy , 2022, Advanced materials.

[10]  C. James,et al.  Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma , 2022, Journal of medicinal chemistry.

[11]  Peizhi Ma,et al.  Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis , 2022, Frontiers in Oncology.

[12]  Peng-Fei Wang,et al.  An updated patent review of IDO1 inhibitors for cancer (2018–2022) , 2022, Expert opinion on therapeutic patents.

[13]  H. Cai,et al.  High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells , 2022, Cell Death & Disease.

[14]  X. Liu,et al.  Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation. , 2022, Cell chemical biology.

[15]  Amit Shard,et al.  PROTACting the kinome with covalent warheads. , 2022, Drug discovery today.

[16]  R. Yang,et al.  A bibliometric analysis of PROTAC from 2001 to 2021. , 2022, European journal of medicinal chemistry.

[17]  Kuojun Zhang,et al.  The development of small-molecule inhibitors targeting HPK1. , 2022, European journal of medicinal chemistry.

[18]  Laiqiang Huang,et al.  Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression , 2022, Journal of Experimental & Clinical Cancer Research.

[19]  Yihua Chen,et al.  Small-Molecule Modulators Targeting SHP2 for Cancer Therapy. , 2022, Anti-cancer agents in medicinal chemistry.

[20]  Xiao-Rong Liu,et al.  LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer , 2022, Frontiers in Oncology.

[21]  T. Vogt,et al.  Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology , 2022, Journal of medicinal chemistry.

[22]  A. Dharamsi,et al.  A perspective on EGFR and Proteasome based targeted therapy for cancer. , 2022, Current drug targets.

[23]  Wenqiu Zhang,et al.  Review of various NAMPT inhibitors for the treatment of cancer , 2022, Frontiers in Pharmacology.

[24]  Y. Yao,et al.  HDAC6-dependent deacetylation of AKAP12 dictates its ubiquitination and promotes colon cancer metastasis. , 2022, Cancer letters.

[25]  T. Yao,et al.  Recent Advances in PROTACs for Drug Targeted Protein Research , 2022, International journal of molecular sciences.

[26]  Ting Chen,et al.  The role of protein arginine N-methyltransferases in inflammation. , 2022, Seminars in cell & developmental biology.

[27]  Ceshi Chen,et al.  Can EGFR be a therapeutic target in breast cancer? , 2022, Biochimica et biophysica acta. Reviews on cancer.

[28]  N. Gray,et al.  Exploring the target scope of KEAP1 E3 ligase-based PROTACs. , 2022, Cell chemical biology.

[29]  M. Chopra,et al.  HDAC6: A unique HDAC family member as a cancer target , 2022, Cellular Oncology.

[30]  Jeong-Mok Kim,et al.  Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway , 2022, Biomedicines.

[31]  D. Jeoung,et al.  Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance , 2022, International journal of molecular sciences.

[32]  A. Carnero,et al.  Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer , 2022, Cells.

[33]  S. Goh,et al.  FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation , 2022, Advanced Science.

[34]  Chunye Zhang,et al.  Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer , 2022, Frontiers in Oncology.

[35]  Liguo Wang,et al.  Chemistries of bifunctional PROTAC degraders. , 2022, Chemical Society reviews.

[36]  Sami I. Alzarea,et al.  An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. , 2022, Chemico-biological interactions.

[37]  Tariq Ahmad Masoodi,et al.  Dysregulated FOXM1 Signaling in the regulation of cancer stem cells. , 2022, Seminars in cancer biology.

[38]  Jun Zhou,et al.  Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives. , 2022, Journal of medicinal chemistry.

[39]  S. Manohar,et al.  The story of EGFR: from signaling pathways to a potent anticancer target. , 2022, Future medicinal chemistry.

[40]  L. Ouyang,et al.  Emerging strategies to overcome resistance to third-generation EGFR inhibitors , 2022, Journal of Hematology & Oncology.

[41]  J. Al-Maghrabi,et al.  Cyclooxygenase-2 immunohistochemical expression is associated with worse prognosis in breast cancer , 2022, Saudi medical journal.

[42]  W. Sippl,et al.  Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity , 2022, International journal of molecular sciences.

[43]  D. Ding,et al.  Semiconducting Polymer Nanoparticles with Surface‐Mimicking Protein Secondary Structure as Lysosome‐Targeting Chimaeras for Self‐Synergistic Cancer Immunotherapy , 2022, Advanced materials.

[44]  Q. You,et al.  Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. , 2022, Journal of medicinal chemistry.

[45]  Zichao Yang,et al.  Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. , 2022, European journal of medicinal chemistry.

[46]  GuanNing Shang,et al.  Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy. , 2022, Seminars in cancer biology.

[47]  Zelin Hu,et al.  Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy. , 2022, European journal of medicinal chemistry.

[48]  Pengyun Li,et al.  Discovery of highly potent and selective CRBN-recruiting EGFRL858R/T790M degraders in vivo. , 2022, European journal of medicinal chemistry.

[49]  L. Sequist,et al.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management , 2022, Nature Reviews Clinical Oncology.

[50]  Shuyi Wang,et al.  Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686. , 2022, European journal of medicinal chemistry.

[51]  I. Seiple,et al.  Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins. , 2022, ACS chemical biology.

[52]  Tsung-Chieh Lin.  Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic Niches , 2022, Cancers.

[53]  S. H. Barghout.  New frontiers in the discovery and development of PROTACs. , 2022, Anti-cancer agents in medicinal chemistry.

[54]  A. Tong,et al.  Targeted protein degradation: mechanisms, strategies and application , 2022, Signal Transduction and Targeted Therapy.

[55]  D. Tenen,et al.  EGFR signaling pathway as therapeutic target in human cancers. , 2022, Seminars in cancer biology.

[56]  Andrew J. Bannister,et al.  Histone post-translational modifications — cause and consequence of genome function , 2022, Nature Reviews Genetics.

[57]  Yukihiro Itoh,et al.  Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). , 2022, Chemical communications.

[58]  Lixia Chen,et al.  Proteolysis-targeting chimera molecules targeting SHP2. , 2022, Future medicinal chemistry.

[59]  Arvind Negi,et al.  Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches , 2022, Chembiochem : a European journal of chemical biology.

[60]  Yongyi Mao,et al.  Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. , 2022, Journal of medicinal chemistry.

[61]  Shu Wang,et al.  Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy. , 2022, Journal of medicinal chemistry.

[62]  Zhe S Chen,et al.  Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera , 2022, Pharmaceutical Research.

[63]  M. Hung,et al.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics , 2022, Nature Reviews Clinical Oncology.

[64]  Massimiliano Gasparrini,et al.  NAMPT: a critical driver and therapeutic target for cancer. , 2022, The international journal of biochemistry & cell biology.

[65]  Yuzhu Hu,et al.  A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization , 2022, Acta pharmaceutica Sinica. B.

[66]  Kenneth M. Yamada,et al.  Ubiquitin ligases: guardians of mammalian development , 2022, Nature Reviews Molecular Cell Biology.

[67]  D. Langley,et al.  PROTAC targeted protein degraders: the past is prologue , 2022, Nature Reviews Drug Discovery.

[68]  Qihua Zhu,et al.  Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. , 2022, Bioorganic chemistry.

[69]  Min Huang,et al.  NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion , 2021, Acta pharmaceutica Sinica. B.

[70]  Kanyi Pu,et al.  Smart Nano‐PROTACs Reprogram Tumor Microenvironment for Activatable Photo‐metabolic Cancer Immunotherapy , 2021, Angewandte Chemie.

[71]  Yuyong Tan,et al.  Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer , 2021, Frontiers in Cell and Developmental Biology.

[72]  L. Altucci,et al.  HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights , 2021, Cancers.

[73]  Yu-bo Zhou,et al.  Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands , 2021, Molecules.

[74]  D. Cui,et al.  ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways , 2021, Frontiers in Oncology.

[75]  A. Roe,et al.  Advances in the Design and Development of PROTAC-mediated HDAC degradation. , 2021, Current topics in medicinal chemistry.

[76]  Jian Yu,et al.  BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade , 2021, Oncogene.

[77]  Xian Chen,et al.  Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation. , 2021, Journal of the American Chemical Society.

[78]  Zhi-wei Wang,et al.  The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy , 2021, Molecular cancer.

[79]  Bin Yu,et al.  Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. , 2021, Pharmacology & therapeutics.

[80]  C. Klein,et al.  Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells , 2021, The Journal of Immunology.

[81]  Y. Xiong,et al.  Advancing targeted protein degradation for cancer therapy , 2021, Nature Reviews Cancer.

[82]  S. Blacklow,et al.  Targeted degradation of the oncogenic phosphatase SHP2 , 2021, bioRxiv.

[83]  K. To,et al.  Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies , 2021, Frontiers in Oncology.

[84]  Kanyi Pu,et al.  Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy , 2021, Nature Communications.

[85]  Jinyun Dong,et al.  PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy , 2021, Frontiers in Pharmacology.

[86]  I. Linney,et al.  Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020) , 2021, Expert opinion on therapeutic patents.

[87]  Bin Yu,et al.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy , 2021, Journal of Hematology & Oncology.

[88]  Wenyi Wei,et al.  Post-translational regulations of PD-L1/PD-1: Mechanisms and opportunities for combined immunotherapy. , 2021, Seminars in cancer biology.

[89]  B. Cravatt,et al.  DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras. , 2021, Journal of the American Chemical Society.

[90]  Guang Yang,et al.  In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). , 2021, Bioorganic chemistry.

[91]  Yongjun Dang,et al.  Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation. , 2021, Journal of the American Chemical Society.

[92]  Xiaomin Luo,et al.  Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. , 2021, European journal of medicinal chemistry.

[93]  Ao Zhang,et al.  The ups, downs and new trends of IDO1 inhibitors. , 2021, Bioorganic chemistry.

[94]  B. Jiang,et al.  Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems. , 2021, European journal of medicinal chemistry.

[95]  Lixia Chen,et al.  Novel PROTACs for degradation of SHP2 protein. , 2021, Bioorganic chemistry.

[96]  S. Zheng,et al.  Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells , 2021, Nature Communications.

[97]  F. Hansen,et al.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives , 2021, Cancers.

[98]  D. P. Nguyen,et al.  Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 , 2021, Journal of the American Chemical Society.

[99]  Zhenjiang Bai,et al.  BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes , 2020, Cancer Cell International.

[100]  M. Emori,et al.  Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review , 2021, Nagoya journal of medical science.

[101]  Zixia Lin,et al.  Emerging role of PD-L1 modification in cancer immunotherapy. , 2021, American journal of cancer research.

[102]  Zhi-wei Wang,et al.  Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  Haiyan Xu,et al.  Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function , 2020, PloS one.

[104]  Kai Wang,et al.  Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti‐tumor immunity in non‐small cell lung cancer , 2020, Drug development research.

[105]  Yingjie Zhang,et al.  Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC , 2020, Molecules.

[106]  M. Zwinderman,et al.  Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). , 2020, European journal of medicinal chemistry.

[107]  T. Minko.  Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer. , 2020, Trends in pharmacological sciences.

[108]  Yun Gao,et al.  The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells , 2020, Cell Death & Disease.

[109]  Haolan Lei,et al.  Discovery of potent small molecule PROTACs targeting mutant EGFR. , 2020, European journal of medicinal chemistry.

[110]  Lisa Y. Zhao,et al.  Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. , 2020, Chemical communications.

[111]  Zhi-wei Wang,et al.  PhotoPROTACs: A Novel Biotechnology for Cancer Treatment. , 2020, Trends in cell biology.

[112]  D. Dimitrov,et al.  Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. , 2020, Cancer cell.

[113]  Jie Xu,et al.  Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets , 2020, Cancer biology & medicine.

[114]  Carolyn R. Bertozzi,et al.  Lysosome-targeting chimaeras for degradation of extracellular proteins , 2020, Nature.

[115]  Ketan Patel,et al.  Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer. , 2020, Nanomedicine.

[116]  Hong-min Liu,et al.  Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. , 2020, European journal of medicinal chemistry.

[117]  A. Stathis,et al.  Targeting BET bromodomain proteins in cancer: The example of lymphomas. , 2020, Pharmacology & therapeutics.

[118]  R. Koch,et al.  DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas , 2020, Journal of Hematology & Oncology.

[119]  Mingliang Wang,et al.  Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. , 2020, Journal of medicinal chemistry.

[120]  Yongcheng Song,et al.  Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy , 2020, Journal of Hematology & Oncology.

[121]  Jianjun Chen,et al.  Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1. , 2020, European journal of medicinal chemistry.

[122]  H. Jeong,et al.  A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology. , 2020, ACS synthetic biology.

[123]  Wenyi Wei,et al.  The diverse roles of SPOP in prostate cancer and kidney cancer , 2020, Nature Reviews Urology.

[124]  W. Chng,et al.  Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor , 2020, bioRxiv.

[125]  Xiaoju Wang,et al.  Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. , 2020, Bioorganic & medicinal chemistry letters.

[126]  Ling He,et al.  ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma , 2020, Aging.

[127]  Lin-jiang Tong,et al.  Design and synthesis of selective degraders of EGFRL858R/T790M mutant. , 2020, European journal of medicinal chemistry.

[128]  Tinghong Ye,et al.  Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1 , 2020, Acta pharmaceutica Sinica. B.

[129]  Daohong Zhou,et al.  Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. , 2020, European journal of medicinal chemistry.

[130]  Wenge Zhu,et al.  Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer , 2020, Scientific Reports.

[131]  Sayed K Goda,et al.  Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[132]  Wenyi Wei,et al.  PROTACs: a novel strategy for cancer therapy. , 2020, Seminars in cancer biology.

[133]  San-qi Zhang,et al.  Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). , 2020, European journal of medicinal chemistry.

[134]  A. Ferrando,et al.  A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity , 2019, Nature Medicine.

[135]  Philip P. Chamberlain,et al.  Development of targeted protein degradation therapeutics , 2019, Nature Chemical Biology.

[136]  J. Chern,et al.  High‐selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma , 2019, Biochemical pharmacology.

[137]  R. Davis,et al.  BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. , 2019, The Journal of clinical investigation.

[138]  A. Letai,et al.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins , 2019, Nature Reviews Molecular Cell Biology.

[139]  Stephanie Jensen,et al.  Specific MHC-I Peptides Are Induced Using PROTACs , 2018, Front. Immunol..

[140]  M. Hung,et al.  Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. , 2018, Cancer research.

[141]  M. Coluccia,et al.  Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature , 2018, Pharmaceuticals.

[142]  I. Mellman,et al.  The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. , 2018, Cell reports.

[143]  Shiming Yang,et al.  Regulation of the master regulator FOXM1 in cancer , 2018, Cell Communication and Signaling.

[144]  Xu Wang,et al.  Targeting the IDO1 pathway in cancer: from bench to bedside , 2018, Journal of Hematology & Oncology.

[145]  V. Baladandayuthapani,et al.  Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma , 2018, Leukemia.

[146]  D. Wainwright,et al.  IDO1 in cancer: a Gemini of immune checkpoints , 2018, Cellular & Molecular Immunology.

[147]  Dennis L. Buckley,et al.  Acute Pharmacologic Degradation of a Stable Antigen Enhances Its Direct Presentation on MHC Class I Molecules , 2018, Front. Immunol..

[148]  A. Ashkenazi,et al.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.

[149]  Y. Taniguchi.  The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins , 2016, International journal of molecular sciences.

[150]  J. Sethi,et al.  Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine , 2016, British journal of pharmacology.

[151]  David L. Vaux,et al.  Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies , 2016, Nature Reviews Cancer.

[152]  W. Kiess,et al.  Physiological and pathophysiological roles of NAMPT and NAD metabolism , 2015, Nature Reviews Endocrinology.

[153]  Zhiwei Wang,et al.  Targeting the ubiquitin pathway for cancer treatment. , 2015, Biochimica et biophysica acta.

[154]  Zhiwei Wang,et al.  Roles of F-box proteins in cancer , 2014, Nature Reviews Cancer.

[155]  S. Sawasdikosol,et al.  HPK1 as a novel target for cancer immunotherapy , 2012, Immunologic research.

[156]  S. Alzabin,et al.  Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation , 2009, The Journal of Immunology.